PHÂN TÍCH THỰC TRẠNG SỬ DỤNG THUỐC THEO ABC/VEN TRONG ĐIỀU TRỊ HỘI CHỨNG VÀNH CẤP TẠI VIỆN TIM THÀNH PHỐ HỒ CHÍ MINH NĂM 2023

Abstract

Introduction: Acute coronary syndrome (ACS) is one of the common cardiovascular diseases with high treatment costs, in which drug costs dominate. To evaluate the reasonableness in managing and using drugs to treat ACS, analyzing the current situation of drug use according to ABC/VEN is necessary. Objective: Analysis of the current status of drug use according to ABC/VEN in the treatment of ACS at the Heart Institute of Ho Chi Minh City. Methods: Cross-sectional description based on retrospective medical record data of all ACS patients meeting sampling criteria at the Ho Chi Minh City Heart Institute from January to December 2023. Results: The research sample included 975 patients with an average age of 63.94 ± 10.33 years; male:female ratio is 2.1:1; 56.71% were diagnosed with unstable angina and 43.29% had acute myocardial infarction. The study recorded 251 brand-name drugs used in treatment with a total budget of 1,898,343,971 VND. ABC analysis shows that groups A, B and C account for 80.70% respectively; 13.45% and 5.85% respectively of the total budget and 6.77%; 13.55% and 79.68%, respectively, of the total amount of brand-name drugs used. VEN analysis noted that group V has 59 brand names (accounting for 23.51% of the total number of brand names and 49.84% of the total budget); Group E has 177 brand names (accounting for 70.52% of the total number of brand names and 49.77% of the total budget); Group N includes 15 brand names (accounting for 5.98% of the total number of brand name drugs and 0.39% of the total budget). Analyzing the ABC/VEN matrix, the project notes that the AV group includes 5 brand-name drugs (Lovenox 60mg/0.6ml, Duoplavin 75mg/100mg, Meronem 1g, Brilinta 90mg, Lovenox 40mg/0.4ml) with a budget of 799,139.710 VND (accounting for 42.10% of the budget) and no drugs belonging to group AN. Conclusion: Using the drug budget in the treatment of ACS at the City Heart Institute. Ho Chi Minh City in 2023 is reasonable with most of the budget spent on essential and essential drugs, with no drugs belonging to the AN group.